CPT® Code 81208

Molecular genetic testing is a critical procedure used to identify specific mutations within the BCR/ABL1 gene, which are frequently associated with chronic myelogenous leukemia (CML). This testing focuses on a particular type of genetic alteration known as a reciprocal translocation, specifically t(9;22). This translocation involves the BCR (breakpoint cluster region) gene located on chromosome 22, commonly referred to as the Philadelphia chromosome, and the ABL1 (V-abl Abelson murine leukemia viral oncogene) gene found on chromosome 9. The resulting fusion gene from this translocation encodes a tyrosine kinase that is unregulated and targets the cytoplasm, leading to cell proliferation without the normal regulatory influence of cytokines. This unregulated growth predisposes individuals to the development of certain cancers, including CML. At the time of initial diagnosis, karyotyping and molecular testing techniques, such as reverse transcription polymerase chain reaction (rtPCR) or fluorescence in situ hybridization (FISH), are essential for defining tumor markers. These markers are crucial for measuring residual disease during and after treatment. The BCR gene contains three distinct breakpoint cluster regions, which are important for identifying the specific type of translocation present. For instance, CPT® Code 81206 is used for identifying the major breakpoint at p210, which occurs in a 5.8 kb major breakpoint cluster region (M-bcr) around exon b3, resulting in the BCR-ABL1 p210 chimeric transcription. Alternatively, CPT® Code 81207 is designated for the minor breakpoint at p190, located in the minor breakpoint cluster region (m-bcr) on intron 1, leading to the fusion of BCR exon 1 with ABL1 exons 2 through 11. CPT® Code 81208 is specifically utilized for identifying other breakpoint cluster regions that are not classified as major or minor, thus providing a comprehensive approach to the genetic analysis of CML.